{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fadcs-in-nsclc-post-elcc-EDX5YlEg","width":444,"version":"1.0","type":"rich","title":"Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/498541bc-a3b7-402b-bf54-a84ef83ac8ed/lung-ss-elcc-podcasticon.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/f8976143-514b-4501-a7a4-82aa6ebb70f1\" height=\"200\" width=\"100%\" title=\"Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen to Egbert F. Smit, MD, PhD; David Planchard, MD, PhD; and  Helena A. Yu, MD, answer audience questions from a live CCO webinar regarding clinical data on antibody–drug conjugates in NSCLC, including biomarker testing, patient selection, and toxicity management."}